These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26418745)

  • 21. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
    Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).
    Reshetnyak AV; Mohanty J; Tomé F; Puleo DE; Plotnikov AN; Ahmed M; Kaur N; Poliakov A; Cinnaiyan AM; Lax I; Schlessinger J
    Proc Natl Acad Sci U S A; 2018 Aug; 115(33):8340-8345. PubMed ID: 30061385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
    Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
    Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
    Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
    Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase.
    Kuo AH; Stoica GE; Riegel AT; Wellstein A
    Oncogene; 2007 Feb; 26(6):859-69. PubMed ID: 16878150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
    Roskoski R
    Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.
    Javanmardi N; Fransson S; Djos A; Umapathy G; Östensson M; Milosevic J; Borenäs M; Hallberg B; Kogner P; Martinsson T; Palmer RH
    Genes Chromosomes Cancer; 2020 Jan; 59(1):50-57. PubMed ID: 31340081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
    Mathivet T; Mazot P; Vigny M
    Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis for ligand reception by anaplastic lymphoma kinase.
    Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
    Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo.
    Lorén CE; Scully A; Grabbe C; Edeen PT; Thomas J; McKeown M; Hunter T; Palmer RH
    Genes Cells; 2001 Jun; 6(6):531-44. PubMed ID: 11442633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.
    Reiff T; Huber L; Kramer M; Delattre O; Janoueix-Lerosey I; Rohrer H
    Development; 2011 Nov; 138(21):4699-708. PubMed ID: 21989914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types.
    Stoica GE; Kuo A; Powers C; Bowden ET; Sale EB; Riegel AT; Wellstein A
    J Biol Chem; 2002 Sep; 277(39):35990-8. PubMed ID: 12122009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism for the activation of the anaplastic lymphoma kinase receptor.
    Reshetnyak AV; Rossi P; Myasnikov AG; Sowaileh M; Mohanty J; Nourse A; Miller DJ; Lax I; Schlessinger J; Kalodimos CG
    Nature; 2021 Dec; 600(7887):153-157. PubMed ID: 34819673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of the ALK receptor in cancer biology.
    Hallberg B; Palmer RH
    Ann Oncol; 2016 Sep; 27 Suppl 3():iii4-iii15. PubMed ID: 27573755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Genomics within and across Bilaterians Illuminates the Evolutionary History of ALK and LTK Proto-Oncogene Origination and Diversification.
    Dornburg A; Wang Z; Wang J; Mo ES; López-Giráldez F; Townsend JP
    Genome Biol Evol; 2021 Jan; 13(1):. PubMed ID: 33196781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
    Stylianou DC; Auf der Maur A; Kodack DP; Henke RT; Hohn S; Toretsky JA; Riegel AT; Wellstein A
    Oncogene; 2009 Sep; 28(37):3296-306. PubMed ID: 19633684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK-activating homologous mutations in LTK induce cellular transformation.
    Roll JD; Reuther GW
    PLoS One; 2012; 7(2):e31733. PubMed ID: 22347506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.
    Yang HL; Eriksson T; Vernersson E; Vigny M; Hallberg B; Palmer RH
    J Exp Zool B Mol Dev Evol; 2007 May; 308(3):269-82. PubMed ID: 17285636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.